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Take Home Message:  
129
Xe MRI provides rapid, sensitive, non-invasive, high spatial resolution and simultaneous 
measurements of pulmonary ventilation, tissue microstructure and gas exchange, and is poised 




Chest x-ray computed tomography (CT) is the imaging modality of choice for the non-invasive, 
quantitative evaluation of chronic lung diseases because thoracic CT protocols are nearly 
ubiquitously available and provide rapid, high-resolution images of airway and parenchymal 
structure and anatomy. Pulmonary magnetic resonance imaging (MRI) has not been used 
clinically, mainly because of complexity (pulmonary MRI signal decays rapidly), cost and 
because conventional MRI is dependent on proton-density (hydrogen atoms in tissue) which is 
exceptionally low (around 0.1 g/cm
3
) in the healthy lung because it is mainly air and not tissue or 
water-filled [1, 2]. Using conventional MRI methods, the lungs mainly appear as dark, signal-
deficient voids and the pulmonary MRI signal is further degraded because of the millions of lung 
air-tissue interfaces that cause local magnetic field distortions, and respiratory and cardiac 
motion.  While anatomical proton MRI of the lung is now developing rapidly to overcome these 
technical limitations, it still does not provide information beyond that of a low-dose CT so there 
is a drive towards functional MRI.  One of these approaches involves the use of inhaled gas 
contrast agents, primarily hyperpolarised (or magnetised) helium-3 (
3
He) and xenon-129 (
129
Xe), 
both of which provide a way to rapidly (<10 s) and directly visualise inhaled gas distribution 
with high spatial resolution (~3 mm x, y and z planes).  Pulmonary functional MRI is also 
possible using inhaled fluorinated gas [3], oxygen-enhanced techniques [4] and free-breathing 
proton methods [5, 6], however hyperpolarised inhaled gas MRI has been the most widely used 
and described.  Because inhaled contrast gases have different resonant frequencies than hydrogen 
protons as used for conventional MRI, these methods inherently have no background signal and 




While inhalation of hyperpolarised gases to measure pulmonary function was originally 
discovered using 
129
Xe [7], the field was dominated by 
3
He MRI until recently because of 
superior 
3
He MRI image quality with low volume (<500 mL) inhaled doses.  However, the 
limited worldwide supply of 
3
He [8] has driven the field back to 
129
Xe gas because it is naturally 
abundant and turnkey polarisation technologies have significantly advanced [9-11]. 
129
Xe also 
has modest solubility in biologic tissues and resonates at different frequencies when dissolved in 
different tissues, so it provides novel alveolar tissue and capillary blood information.  Here, we 
provide an overview of the key concepts and methods for 
129
Xe MRI, discuss the current state-
of-the-art and how 
129




Xe MRI work? 
129
Xe MRI is dependent on equipment that polarises 
129
Xe atoms which effectively increases the 
nuclear polarisation by ~100,000 times.  Commercial (Polarean Inc., Durham, NC; Xemed LLC, 
Durham, NH) and custom-built [10, 11] polariser systems operate via spin-exchange optical 
pumping [12] whereby circularly polarised light bombards a glass cell housing rubidium and 
129
Xe. The circularly polarised light is absorbed by rubidium and subsequent collisions between 
polarised rubidium and 
129
Xe transfer angular momentum to 
129
Xe and increase its nuclear-spin 
polarisation.  Typically, isotopically enriched 
129
Xe (~86% by volume) is used to further increase 
the fraction of 
129
Xe atoms that are polarised in a given volume.  
129
Xe flows through the glass 
cell at a constant rate and the hyperpolarised 
129
Xe is frozen as it leaves the cell and remains 
frozen until the desired amount is accumulated, upon which it is thawed and dispensed into a bag 
for patient inhalation.  The 
129
Xe flow rate through the cell can be adjusted to accumulate the 
desired 
129
Xe dose within a desired time frame.  
129
Xe doses vary from 250 mL up to 1.0 L [13], 
 
 
and doses are typically diluted up to 1.0 L using medical-grade nitrogen (N2) or helium-4.  
129
Xe 
hyperpolariser equipment is typically located in a small room adjacent to the MRI suite, within 
close proximity to deliver the polarised gas to the patient as quickly as possible. 
 
129
Xe MRI is feasible on both 1.5 T and 3.0 T field strength scanners. To acquire the signal 
however, a radiofrequency coil is fitted around the patient chest and this is specifically tuned to 
the resonance frequency of 
129
Xe.  There are a number of different 
129
Xe coils, however as shown 
in Figure 1, the most common are quadrature rigid birdcage or flexible vests (Clinical MR 
Solutions, Brookfield, WI; RAPID Biomedical, Rimpar, Germany).  Rigid birdcage coils provide 
more homogeneous MRI signal throughout the lungs (ie, no artifactual differences in MRI signal 
that are unrelated to anatomy) and increased signal-to-noise but they have patient size 
limitations; flexible vest coils can accommodate a larger range of patient sizes but may require 
additional image corrections after MRI acquisition [14] to account for signal differences caused 
by the way the patient and coil interact.  Additional receive array-coils may be placed on the 
patients’ chest inside the rigid or flexible design coils and this improves signal-to-noise ratios 
and accelerates acquisition times which enables very short breath-hold scans (~5 seconds).  
Figure 1A shows 
129
Xe MRI equipment including hyperpolariser, gas delivery bag and 
radiofrequency coils, and patient set-up in MRI scanner.  
 
129
Xe MRI is primarily performed under breath-hold conditions, though dynamic multi-breath 
protocols have also been applied [15].  While laying supine, patients are coached to inhale the 
gas mixture from passive end expiration or functional residual capacity and hold their breath 





acquisitions may include static ventilation, diffusion-weighted or dissolved-phase.  Static 
ventilation images are the most commonly reported 
129
Xe MRI acquisition and this provides 
regional maps of pulmonary gas distribution.  A conventional proton (
1
H) image is also typically 
acquired in the same scanning session and at the same lung volume so that the anatomical and 
functional images may be co-registered to distinguish the edges of the thoracic cavity during 
image analysis and segmentation.  Figure 1B shows a 
129
Xe gas static ventilation coronal image 
(cyan) and corresponding anatomical proton image (greyscale), and the two co-registered 
demonstrating a regional ventilation map.  A corresponding CT slice is also shown in Figure 1 as 
well as the 3D segmented airway tree (yellow) which may be co-registered to the ventilation map 
to demonstrate structure-function relationships. 
Diffusion-weighted 
129
Xe MRI methods may also be employed and these estimate the self-
diffusion of 
129
Xe gas within the terminal airways and their restriction within the airspaces on a 
voxel-wise basis [16], which provides an excellent surrogate measurement of alveolar and 
terminal bronchiole enlargement. 
 
129
Xe has a large, loosely-bound electron cloud, making it sensitive to its surroundings and 
soluble in biological tissue; once dissolved in biological tissues, 
129
Xe exhibits a different 
resonance frequency.  Thus, 
129
Xe MRI can also provide in vivo measurements of pulmonary gas 
exchange [17, 18].  The so-called dissolved-state refers to 
129
Xe dissolved in the alveolar 
membrane and in red blood cells.  
129
Xe that has diffused into biological tissues experiences a 
different chemical environment and this is reflected via a shift in the 
129
Xe resonance frequency 
(chemical shift) from gaseous 
129
Xe, as shown in Figure 2B.  In the same manner, there is also a 
difference in the resonance frequency between 
129
Xe in the tissue and 
129
Xe in the blood, which 
 
 
enables simultaneous, independent imaging of these three states or compartments: 1) gas, 2) 
tissue barrier plus plasma, and 3) red blood cell.  The gas state reflects the inhaled gas and has 
the largest measurable signal.  
129
Xe dissolved in the tissue barrier and blood plasma have 
indistinguishable chemical shifts and combine for the second largest measurable signal with a 
~197 ppm shift from gaseous 
129
Xe [19].  
129
Xe dissolved in red blood cells exhibits an 
additional ~20 ppm shift beyond the tissue-plasma signal and makes up the smallest, measurable 
129
Xe signal [19]; moreover, the red blood cell signal is oxygen-dependent and may undergo 
another measurable ~5 ppm shift based on blood oxygenation [20].  Tuning the scanner allows 
acquisition of images of all three compartments, and acquisition protocols have been developed 
to simultaneously acquire quantitative images from all three compartments within a single 
breath-hold [18].  
 
Current state-of-the-art  
129
Xe MRI methods have an excellent safety profile in patients with respiratory disease [21, 22], 
including asthma [23-25], COPD [16, 26-29], cystic fibrosis [30-32], pulmonary vascular disease 
[33], idiopathic pulmonary fibrosis [34, 35], lung cancer [36] and lymphangioleiomyomatosis 
[37]. 
 
In healthy volunteers, 
29
Xe gas distribution is typically highly homogeneous and gas signal fills 
the entire lung whereas in patients with lung disease such as in Figure 1, focal MRI signal voids 
or ventilation defects and patchy gas distribution are often observed.  Ventilation defects are 
commonly quantified as the ventilation defect percent (VDP) [38] – the volume of ventilation 
defects normalised to the thoracic cavity volume. In a similar manner, using diffusion-weighted 





Xe ADC is low in healthy participants and increases with increasing airspace size 
and the extent of emphysema [16, 26].  Diffusion-weighted MRI may also be used to generate 
morphological airspace measurements [39, 40], for example mean linear intercept analogous to 
histology.  Normalised biomarkers of the ratio of 
129
Xe dissolved in the tissue barrier and red 
blood cells [18], have been shown to be particularly relevant in pulmonary fibrosis.  A unique 
feature of 
129
Xe MRI is that it provides a way to regionally quantify gas exchange [17, 41] in 
regions of the lung that are ventilated and models have been developed to extract subcomponents 
of gas exchange and structural measurements [42-44]. 
At the current time, 
129
Xe MRI is approved for clinical use in the United Kingdom and clinical 




Xe MRI likely to be used in the future? 
The infrastructure needed to enable 
129
Xe MRI is available in ~12 respiratory imaging sites 
worldwide using a wide variety of different scanners, polarisers and coils.  Whilst technical 
developments will enable faster 
129
Xe polarisation times and larger volumes of polarised gas, 
multi-centre clinical trials are now poised to demonstrate the inter- and intra-site reproducibility 
of 
129
Xe MRI biomarkers so that clinical trials of new treatments and interventions using MRI 
may be powered.  A comprehensive 
129
Xe examination (including localiser scan, anatomical 
scan, ventilation, diffusion-weighted, perfusion and gas exchange scans) in a patient may be 
easily performed within 15 minutes, often with patients inside the MRI bore for approximately 5 
minutes and this is certainly compatible with current clinical imaging workflows. 
Highly sensitive 
129
Xe MRI VDP promises therapy studies utilising smaller sample sizes to 
evaluate response to therapy.  The broad array of 
129
Xe MRI biomarkers may provide endpoints 
 
 
for clinical trials of novel treatments for asthma, COPD, cystic fibrosis and especially pulmonary 
fibrosis.  The spatially resolved functional information provided by 
129
Xe MRI may perhaps 
guide placement of endobronchial valves, which are currently guided using structural 
information from CT.  Moreover, 
129
Xe MRI may provide a way to generate quantitative 
pathological evidence for treatment responses, for example following bronchial thermoplasty 
[45, 46] or novel biologic treatments for asthma [47], where patients experience improved 
quality of life and reduced exacerbation frequency often in the absence of FEV1 improvements.  
Another valuable application of 
129
Xe MRI may be in the prediction of pulmonary exacerbations, 
which has been demonstrated using 
3
He MRI [48, 49].  Because 
129
Xe MRI appears to be more 
sensitive to ventilation abnormalities [23, 26], it is expected to also predict or explain pulmonary 
exacerbations of COPD, cystic fibrosis and asthma. 
It remains difficult to predict response to treatment in many respiratory diseases, which is 
becoming increasingly important as novel, expensive therapies continue to be developed.  
Imaging phenotypes are widely recognised in COPD and pulmonary fibrosis and the 
combination of available 
129
Xe MRI biomarkers may provide novel phenotypes to support 
regulatory and treatment decisions. Moreover, 
129
Xe MRI provides a regional map of lung 
structure-function that can be likened to a fingerprint or “lung-print”, to support individualised 
therapy decisions or n=1 studies in individual patients.   
129
Xe MRI is particularly invaluable for longitudinal monitoring of disease progression, disease 
phenotypes and/or treatment response (in and outside of clinical trials) because it poses no 
radiation burden on patients.  The lack of ionising radiation is particularly needed for 





Xe MRI provides rapid, sensitive, non-invasive and simultaneous measurements 
of pulmonary ventilation, lung tissue microstructure as well as diffusion within the alveolus and 
into the alveolar tissue and red blood cells, providing new opportunities to more deeply 





1. Bergin CJ, Glover GM, Pauly J. Magnetic resonance imaging of lung parenchyma. J 
Thorac Imaging 1993: 8(1): 12-17. 
2. Johnson KM, Fain SB, Schiebler ML, Nagle S. Optimized 3D ultrashort echo time 
pulmonary MRI. Magn Reson Med 2013: 70(5): 1241-1250. 
3. Couch MJ, Ball IK, Li T, Fox MS, Ouriadov AV, Biman B, Albert MS. Inert fluorinated 
gas MRI: a new pulmonary imaging modality. NMR Biomed 2014: 27(12): 1525-1534. 
4. Edelman RR, Hatabu H, Tadamura E, Li W, Prasad PV. Noninvasive assessment of 
regional ventilation in the human lung using oxygen-enhanced magnetic resonance imaging. Nat 
Med 1996: 2(11): 1236-1239. 
5. Bergin CJ, Pauly JM, Macovski A. Lung parenchyma: projection reconstruction MR 
imaging. Radiology 1991: 179(3): 777-781. 
6. Bauman G, Puderbach M, Deimling M, Jellus V, Chefd'hotel C, Dinkel J, Hintze C, 
Kauczor HU, Schad LR. Non-contrast-enhanced perfusion and ventilation assessment of the 
human lung by means of fourier decomposition in proton MRI. Magn Reson Med 2009: 62(3): 
656-664. 
7. Albert MS, Cates GD, Driehuys B, Happer W, Saam B, Springer CS, Jr., Wishnia A. 
Biological magnetic resonance imaging using laser-polarized 129Xe. Nature 1994: 370(6486): 
199-201. 
8. Shea DA, Morgan D. The helium-3 shortage: Supply, demand, and options for congress. 
In; 2010: Congressional Research Service, Library of Congress; 2010. 
9. Hersman FW, Ruset IC, Ketel S, Muradian I, Covrig SD, Distelbrink J, Porter W, Watt 
D, Ketel J, Brackett J, Hope A, Patz S. Large production system for hyperpolarized 129Xe for 
human lung imaging studies. Acad Radiol 2008: 15(6): 683-692. 
10. Nikolaou P, Coffey AM, Walkup LL, Gust BM, Whiting N, Newton H, Barcus S, 
Muradyan I, Dabaghyan M, Moroz GD, Rosen MS, Patz S, Barlow MJ, Chekmenev EY, 
Goodson BM. Near-unity nuclear polarization with an open-source 129Xe hyperpolarizer for 
NMR and MRI. Proc Natl Acad Sci U S A 2013: 110(35): 14150-14155. 
11. Norquay G, Parnell SR, Xu X, Parra-Robles J, Wild JM. Optimized production of 
hyperpolarized 129Xe at 2 bars for in vivo lung magnetic resonance imaging. J Appl Phys 2013: 
113(4): 044908. 
12. Walker TG, Happer W. Spin-exchange optical pumping of noble-gas nuclei. Rev Mod 
Phys 1997: 69(2): 629. 
13. He M, Robertson SH, Kaushik SS, Freeman MS, Virgincar RS, Davies J, Stiles J, Foster 
WM, McAdams HP, Driehuys B. Dose and pulse sequence considerations for hyperpolarized 
(129)Xe ventilation MRI. Magn Reson Imaging 2015: 33(7): 877-885. 
14. He M, Driehuys B, Que LG, Huang YT. Using Hyperpolarized 129Xe MRI to Quantify 
the Pulmonary Ventilation Distribution. Acad Radiol 2016: 23(12): 1521-1531. 
15. Horn FC, Rao M, Stewart NJ, Wild JM. Multiple breath washout of hyperpolarized (129) 
Xe and (3) He in human lungs with three-dimensional balanced steady-state free-precession 
imaging. Magn Reson Med 2017: 77(6): 2288-2295. 
16. Kaushik SS, Cleveland ZI, Cofer GP, Metz G, Beaver D, Nouls J, Kraft M, Auffermann 
W, Wolber J, McAdams HP, Driehuys B. Diffusion-weighted hyperpolarized 129Xe MRI in 
healthy volunteers and subjects with chronic obstructive pulmonary disease. Magn Reson Med 
2011: 65(4): 1154-1165. 
 
 
17. Qing K, Ruppert K, Jiang Y, Mata JF, Miller GW, Shim YM, Wang C, Ruset IC, 
Hersman FW, Altes TA, Mugler JP, 3rd. Regional mapping of gas uptake by blood and tissue in 
the human lung using hyperpolarized xenon-129 MRI. J Magn Reson Imaging 2014: 39(2): 346-
359. 
18. Kaushik SS, Robertson SH, Freeman MS, He M, Kelly KT, Roos JE, Rackley CR, Foster 
WM, McAdams HP, Driehuys B. Single-breath clinical imaging of hyperpolarized (129)Xe in 
the airspaces, barrier, and red blood cells using an interleaved 3D radial 1-point Dixon 
acquisition. Magn Reson Med 2016: 75(4): 1434-1443. 
19. Mugler JP, 3rd, Driehuys B, Brookeman JR, Cates GD, Berr SS, Bryant RG, Daniel TM, 
de Lange EE, Downs JH, 3rd, Erickson CJ, Happer W, Hinton DP, Kassel NF, Maier T, Phillips 
CD, Saam BT, Sauer KL, Wagshul ME. MR imaging and spectroscopy using hyperpolarized 
129Xe gas: preliminary human results. Magn Reson Med 1997: 37(6): 809-815. 
20. Norquay G, Leung G, Stewart NJ, Wolber J, Wild JM. (129) Xe chemical shift in human 
blood and pulmonary blood oxygenation measurement in humans using hyperpolarized (129) Xe 
NMR. Magn Reson Med 2017: 77(4): 1399-1408. 
21. Shukla Y, Wheatley A, Kirby M, Svenningsen S, Farag A, Santyr GE, Paterson NA, 
McCormack DG, Parraga G. Hyperpolarized 129Xe magnetic resonance imaging: tolerability in 
healthy volunteers and subjects with pulmonary disease. Acad Radiol 2012: 19(8): 941-951. 
22. Driehuys B, Martinez-Jimenez S, Cleveland ZI, Metz GM, Beaver DM, Nouls JC, 
Kaushik SS, Firszt R, Willis C, Kelly KT, Wolber J, Kraft M, McAdams HP. Chronic 
obstructive pulmonary disease: safety and tolerability of hyperpolarized 129Xe MR imaging in 
healthy volunteers and patients. Radiology 2012: 262(1): 279-289. 
23. Svenningsen S, Kirby M, Starr D, Leary D, Wheatley A, Maksym GN, McCormack DG, 
Parraga G. Hyperpolarized (3) He and (129) Xe MRI: differences in asthma before 
bronchodilation. J Magn Reson Imaging 2013: 38(6): 1521-1530. 
24. Qing K, Mugler JP, 3rd, Altes TA, Jiang Y, Mata JF, Miller GW, Ruset IC, Hersman 
FW, Ruppert K. Assessment of lung function in asthma and COPD using hyperpolarized 129Xe 
chemical shift saturation recovery spectroscopy and dissolved-phase MRI. NMR Biomed 2014: 
27(12): 1490-1501. 
25. Ebner L, He M, Virgincar RS, Heacock T, Kaushik SS, Freemann MS, McAdams HP, 
Kraft M, Driehuys B. Hyperpolarized 129Xenon Magnetic Resonance Imaging to Quantify 
Regional Ventilation Differences in Mild to Moderate Asthma: A Prospective Comparison 
Between Semiautomated Ventilation Defect Percentage Calculation and Pulmonary Function 
Tests. Invest Radiol 2017: 52(2): 120-127. 
26. Kirby M, Svenningsen S, Owrangi A, Wheatley A, Farag A, Ouriadov A, Santyr GE, 
Etemad-Rezai R, Coxson HO, McCormack DG, Parraga G. Hyperpolarized 3He and 129Xe MR 
imaging in healthy volunteers and patients with chronic obstructive pulmonary disease. 
Radiology 2012: 265(2): 600-610. 
27. Virgincar RS, Cleveland ZI, Kaushik SS, Freeman MS, Nouls J, Cofer GP, Martinez-
Jimenez S, He M, Kraft M, Wolber J, McAdams HP, Driehuys B. Quantitative analysis of 
hyperpolarized 129Xe ventilation imaging in healthy volunteers and subjects with chronic 
obstructive pulmonary disease. NMR Biomed 2013: 26(4): 424-435. 
28. Matin TN, Rahman N, Nickol AH, Chen M, Xu X, Stewart NJ, Doel T, Grau V, Wild 
JM, Gleeson FV. Chronic Obstructive Pulmonary Disease: Lobar Analysis with Hyperpolarized 
(129)Xe MR Imaging. Radiology 2017: 282(3): 857-868. 
 
 
29. Ruppert K, Qing K, Patrie JT, Altes TA, Mugler JP, 3rd. Using Hyperpolarized Xenon-
129 MRI to Quantify Early-Stage Lung Disease in Smokers. Acad Radiol 2019: 26(3): 355-366. 
30. Kanhere N, Couch MJ, Kowalik K, Zanette B, Rayment JH, Manson D, Subbarao P, 
Ratjen F, Santyr G. Correlation of Lung Clearance Index with Hyperpolarized (129)Xe Magnetic 
Resonance Imaging in Pediatric Subjects with Cystic Fibrosis. Am J Respir Crit Care Med 2017: 
196(8): 1073-1075. 
31. Couch MJ, Thomen R, Kanhere N, Hu R, Ratjen F, Woods J, Santyr G. A two-center 
analysis of hyperpolarized (129)Xe lung MRI in stable pediatric cystic fibrosis: Potential as a 
biomarker for multi-site trials. J Cyst Fibros 2019: 18(5): 728-733. 
32. Rayment JH, Couch MJ, McDonald N, Kanhere N, Manson D, Santyr G, Ratjen F. 
Hyperpolarised (129)Xe magnetic resonance imaging to monitor treatment response in children 
with cystic fibrosis. Eur Respir J 2019: 53(5). 
33. Dahhan T, Kaushik SS, He M, Mammarappallil JG, Tapson VF, McAdams HP, Sporn 
TA, Driehuys B, Rajagopal S. Abnormalities in hyperpolarized (129)Xe magnetic resonance 
imaging and spectroscopy in two patients with pulmonary vascular disease. Pulm Circ 2016: 
6(1): 126-131. 
34. Wang JM, Robertson SH, Wang Z, He M, Virgincar RS, Schrank GM, Smigla RM, 
O'Riordan TG, Sundy J, Ebner L, Rackley CR, McAdams P, Driehuys B. Using hyperpolarized 
(129)Xe MRI to quantify regional gas transfer in idiopathic pulmonary fibrosis. Thorax 2018: 
73(1): 21-28. 
35. Weatherley ND, Stewart NJ, Chan HF, Austin M, Smith LJ, Collier G, Rao M, Marshall 
H, Norquay G, Renshaw SA, Bianchi SM, Wild JM. Hyperpolarised xenon magnetic resonance 
spectroscopy for the longitudinal assessment of changes in gas diffusion in IPF. Thorax 2019: 
74(5): 500-502. 
36. Tahir BA, Hughes PJC, Robinson SD, Marshall H, Stewart NJ, Norquay G, Biancardi A, 
Chan HF, Collier GJ, Hart KA, Swinscoe JA, Hatton MQ, Wild JM, Ireland RH. Spatial 
Comparison of CT-Based Surrogates of Lung Ventilation With Hyperpolarized Helium-3 and 
Xenon-129 Gas MRI in Patients Undergoing Radiation Therapy. Int J Radiat Oncol Biol Phys 
2018: 102(4): 1276-1286. 
37. Walkup LL, Roach DJ, Hall CS, Gupta N, Thomen RP, Cleveland ZI, McCormack FX, 
Woods JC. Cyst Ventilation Heterogeneity and Alveolar Airspace Dilation as Early Disease 
Markers in Lymphangioleiomyomatosis. Ann Am Thorac Soc 2019: 16(8): 1008-1016. 
38. Kirby M, Heydarian M, Svenningsen S, Wheatley A, McCormack DG, Etemad-Rezai R, 
Parraga G. Hyperpolarized 3He magnetic resonance functional imaging semiautomated 
segmentation. Acad Radiol 2012: 19(2): 141-152. 
39. Sukstanskii AL, Yablonskiy DA. Lung morphometry with hyperpolarized 129Xe: 
theoretical background. Magn Reson Med 2012: 67(3): 856-866. 
40. Thomen RP, Quirk JD, Roach D, Egan-Rojas T, Ruppert K, Yusen RD, Altes TA, 
Yablonskiy DA, Woods JC. Direct comparison of (129) Xe diffusion measurements with 
quantitative histology in human lungs. Magn Reson Med 2017: 77(1): 265-272. 
41. Kaushik SS, Freeman MS, Cleveland ZI, Davies J, Stiles J, Virgincar RS, Robertson SH, 
He M, Kelly KT, Foster WM, McAdams HP, Driehuys B. Probing the regional distribution of 
pulmonary gas exchange through single-breath gas- and dissolved-phase 129Xe MR imaging. J 
Appl Physiol (1985) 2013: 115(6): 850-860. 
42. Chang YV. MOXE: a model of gas exchange for hyperpolarized 129Xe magnetic 
resonance of the lung. Magn Reson Med 2013: 69(3): 884-890. 
 
 
43. Stewart NJ, Leung G, Norquay G, Marshall H, Parra-Robles J, Murphy PS, Schulte RF, 
Elliot C, Condliffe R, Griffiths PD, Kiely DG, Whyte MK, Wolber J, Wild JM. Experimental 
validation of the hyperpolarized (129) Xe chemical shift saturation recovery technique in healthy 
volunteers and subjects with interstitial lung disease. Magn Reson Med 2015: 74(1): 196-207. 
44. Stewart NJ, Chan HF, Hughes PJC, Horn FC, Norquay G, Rao M, Yates DP, Ireland RH, 
Hatton MQ, Tahir BA, Ford P, Swift AJ, Lawson R, Marshall H, Collier GJ, Wild JM. 
Comparison of (3) He and (129) Xe MRI for evaluation of lung microstructure and ventilation at 
1.5T. J Magn Reson Imaging 2018. 
45. Castro M, Rubin AS, Laviolette M, Fiterman J, De Andrade Lima M, Shah PL, Fiss E, 
Olivenstein R, Thomson NC, Niven RM, Pavord ID, Simoff M, Duhamel DR, McEvoy C, 
Barbers R, Ten Hacken NH, Wechsler ME, Holmes M, Phillips MJ, Erzurum S, Lunn W, Israel 
E, Jarjour N, Kraft M, Shargill NS, Quiring J, Berry SM, Cox G. Effectiveness and safety of 
bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-
blind, sham-controlled clinical trial. Am J Respir Crit Care Med 2010: 181(2): 116-124. 
46. Chupp G, Laviolette M, Cohn L, McEvoy C, Bansal S, Shifren A, Khatri S, Grubb GM, 
McMullen E, Strauven R, Kline JN. Long-term outcomes of bronchial thermoplasty in subjects 
with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre 
studies. Eur Respir J 2017: 50(2). 
47. McGregor MC, Krings JG, Nair P, Castro M. Role of Biologics in Asthma. Am J Respir 
Crit Care Med 2019: 199(4): 433-445. 
48. Kirby M, Pike D, Coxson HO, McCormack DG, Parraga G. Hyperpolarized (3)He 
ventilation defects used to predict pulmonary exacerbations in mild to moderate chronic 
obstructive pulmonary disease. Radiology 2014: 273(3): 887-896. 
49. Mummy DG, Kruger SJ, Zha W, Sorkness RL, Jarjour NN, Schiebler ML, Denlinger LC, 
Evans MD, Fain SB. Ventilation defect percent in helium-3 magnetic resonance imaging as a 































Figure 1. 129Xe MRI infrastructure requirements and image acquisition
(A) 129Xe hyperpolariser, gas delivery bag, radiofrequency coils (flexible vest and
rigid birdcage), and patient set-up for MRI. (B) 129Xe gas, anatomical proton (1H), and
CT airways (yellow) images co-registered (cyan), with 129Xe gas, tissue plus plasma
and red blood cell (RBC) spectrum.
